Randomized cost-effectiveness trial of group interpersonal psychotherapy (IPT) for prisoners with major depression. 2019

Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
Division of Public Health.

OBJECTIVE This study tested the effectiveness and cost-effectiveness of interpersonal psychotherapy (IPT) for major depressive disorder (MDD) among prisoners. It is the first fully powered randomized trial of any treatment (pharmacological or psychosocial) targeting MDD among incarcerated individuals. METHODS One hundred eighty-one male (n = 117) and female (n = 64) prisoners from prison facilities in 2 states were randomized to group IPT (delivered by master's-level and nonspecialist prison counselors) for MDD plus prison treatment as usual (TAU) or to TAU alone. Participants' average age was 39 (range = 20-61); 20% were African American and 19% were Hispanic. Outcomes assessed at posttreatment and 3-month follow-up included depressive symptoms (primary; assessed using the Hamilton Rating Scale for Depression), suicidality (assessed with the Beck Scale for Suicide Ideation and Beck Hopelessness Scale), in-prison functioning (i.e., enrollment in correctional programs; discipline reports; aggression/victimization; and social support), remission from MDD, and posttraumatic stress disorder symptoms. RESULTS IPT reduced depressive symptoms, hopelessness, and posttraumatic stress disorder symptoms, and increased rates of MDD remission relative to prison TAU alone. Effects on hopelessness were particularly strong. Cost per patient was $2,054 including costs for IPT training and supervision or $575 without these costs. For providers running their second or subsequent IPT group, cost per additional week in remission from MDD (relative to TAU alone) was $524 ($148 excluding training and supervision costs, which would not be needed for established programs). CONCLUSIONS IPT is effective and cost-effective and we recommend its use for MDD among prisoners. It is currently the only treatment for MDD evaluated among incarcerated individuals. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011329 Prisoners Persons deprived of their liberty; those held is against their will, or who are kept in confinement or custody. Detained Persons,Hostages,Imprisoned Individuals,Incarcerated Individuals,Inmates,Detained Person,Hostage,Imprisoned Individual,Incarcerated Individual,Individual, Imprisoned,Individual, Incarcerated,Inmate,Person, Detained,Prisoner
D011615 Psychotherapy, Group A form of therapy in which two or more patients participate under the guidance of one or more psychotherapists for the purpose of treating emotional disturbances, social maladjustments, and psychotic states. Group Therapy,Group Psychotherapy,Therapy, Group
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
January 2001, The Journal of psychotherapy practice and research,
Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
February 2021, Journal of affective disorders,
Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
January 2007, International journal of technology assessment in health care,
Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
January 2021, International journal of group psychotherapy,
Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
November 2012, European archives of psychiatry and clinical neuroscience,
Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
December 2023, Journal of psychiatric research,
Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
June 2003, JAMA,
Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
April 2010, Archives of women's mental health,
Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
November 2000, Journal of affective disorders,
Jennifer E Johnson, and Robert L Stout, and Ted R Miller, and Caron Zlotnick, and Louis A Cerbo, and Joel T Andrade, and Jessica Nargiso, and Joseph Bonner, and Shannon Wiltsey-Stirman
February 2001, Journal of the American Academy of Child and Adolescent Psychiatry,
Copied contents to your clipboard!